未登录Changing landscape of HCV treatment in Germany: Data from a large real-world cohort 2014-2017
Petersen, J.; Olah, K.; Lorenzen, T.; Stefan, U.; Harder, C.; Wursthorn, K.; Plettenberg, A.; Andre, B.; Kathrin, M.; Stoehr, A.; Buggisch, P. .png)
分享.png)
收藏S2k guideline: HPV-associated lesions of the external genital region and the anus - anogenital warts and precancerous lesions of the vulva, the penis, and the peri- and intra-anal skin (short version)Gross, Gerd E.; Werner, Ricardo N.; Becker, Juergen C.; Brockmeyer, Norbert H.; Esser, Stefan; Hampl, Monika; Hommel, Sara; Jongen, Johannes; Mestel, Dominik S.; Meyer, Thomas; Petry, Karl U.; Plettenberg, Andreas; Pueschel, Klaus; Schneede, Peter; Schoefer, Helmut; Sotlar, Karl; Weyandt, Gerhard; Wieland, Ulrike; Wiese-Posselt, Miriam; Nast, Alexander 分享 收藏 Strong decrease of patients with advanced liver disease and more adherence problems to HCV therapy as DAA regimen enter third year of existence in GermanyPetersen, J.; Wursthorn, K.; Olah, K.; Lorenzen, T.; Plettenberg, A.; Unger, S.; Czaja-Harder, C.; Burchard, A.; Matschenz, K.; Stoehr, A.; Buggisch, P. 分享 收藏 FAILURE WITH DAA REGIMENS IN A HIGH VOLUME TREATMENT CENTER UNDER REAL LIFE CONDITIONSPetersen, J.; Wursthorn, K.; Olah, K.; Lorenzen, T.; Plettenberg, A.; Unger, S.; Czaja-Harder, C.; Matschenz, K.; Stoehr, A.; Buggisch, P. 分享 收藏 Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ARTLambert-Niclot, S.; George, E. C.; Pozniak, A.; White, E.; Schwimmer, C.; Jessen, H.; Johnson, M.; Dunn, D.; Perno, C. F.; Clotet, B.; Plettenberg, A.; Blaxhult, A.; Palmisano, L.; Wittkop, L.; Calvez, V.; Marcelin, A. G.; Raffi, F. 分享 收藏 Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trialPollard, Richard B.; Rockstroh, Jurgen K.; Pantaleo, Giuseppe; Asmuth, David M.; Peters, Barry; Lazzarin, Adriano; Garcia, Felipe; Ellefsen, Kim; Podzamczer, Daniel; van Lunzen, Jan; Arasteh, Keikawus; Schuermann, Dirk; Clotet, Bonaventura; Hardy, W. David; Mitsuyasu, Ronald; Moyle, Graeme; Plettenberg, Andreas; Fisher, Martin; Fatkenheuer, Gerd; Fischl, Margaret; Taiwo, Babafemi; Baksaas, Ingebjorg; Jolliffe, Darren; Persson, Stefan; Jelmert, Oyvind; Hovden, Arnt-Ove; Sommerfelt, Maja A.; Wendel-Hansen, Vidar; Sorensen, Birger 分享 收藏 REAL-WORLD TREATMENT WITH FIRST GENERATION TRIPLE THERAPY FOR HCV-GT1 DIFFICULT-TO-TREAT PATIENTS: FINAL RESULTS OF AN OBSERVATIONAL STUDY IN PATIENTS WITH ADVANCED LIVER DISEASE AND NONRESPONSEPetersen, J.; Olah, K.; Unger, S.; Lorenzen, T.; Kuhlendahl, F.; Wursthorn, K.; Plettenberg, A.; Stoehr, A.; Czaja-Harder, C.; Buggisch, P. 分享 收藏 分享 收藏 INCIDENCE AND RISK FACTORS OF HERPES ZOSTER AMONG HIV-POSITIVE PATIENTS IN THE COHORT OF THE GERMAN COMPETENCE NETWORK FOR HIV/AIDS (KOMPNET)Michalik, C.; Jansen, K.; Haastert, B.; Dupke, S.; Esser, S.; Plettenberg, A.; Koeppe, S.; Guignard, A.; Skaletz-Rorowski, A.; Brockmeyer, N. H. 分享 收藏 REAL WORD EXPERIENCE WITH TRIPLE THERAPY FOR HCV GT1 PATIENTS IN DIFFICULT TO TREAT PATIENTS: SEVERE ADVERSE EVENTS AND HIGH RATES OF VIROLOGICAL BREAK-THROUGHPetersen, J.; Matschenz, K.; Olah, K.; Unger, S.; Lorenzen, T.; Kuhlendahl, F.; Plettenberg, A.; Stoehr, A.; Wolski, H.; Voelker, K.; Czaja-Harder, C.; Buggisch, P. 分享 收藏 Bioavailability of Extended-Release Nevirapine 400 and 300 mg in HIV-1: A Multicenter, Open-Label StudyBattegay, Manuel; Arasteh, Keikawus; Plettenberg, Andreas; Bogner, Johannes R.; Livrozet, Jean-Michel; Witt, Mallory D.; Mossdorf, Erik; Yong, Chan-Loi; Zhang, Wei; Macha, Sreeraj; Berger, Frank; Stern, Jerry; Robinson, Patrick; Quinson, Anne-Marie 分享 收藏 分享 收藏 分享 收藏 Orale candidiasisReinel, Dieter; Plettenberg, Andreas; Seebacher, Claus; Abeck, Dietrich; Brasch, Jochen; Cornely, Oliver; Effendy, Isaak; Ginter-Hanselmayer, Gabriele; Haake, Norbert; Hamm, Gudrun; Hipler, Uta-Christina; Hof, Herbert; Korting, Hans Christian; Mayser, Peter; Ruhnke, Markus; Schlacke, Kurt-Heiner; Tietz, Hans-Juergen 分享 收藏 Evolving characteristics of toxoplasmosis in patients infected with human immunodeficiency virus-1:: clinical course and Toxoplasma gondii-specific immune responsesHoffmann, C.; Ernst, M.; Meyer, P.; Wolf, E.; Rosenkranz, T.; Plettenberg, A.; Stoehr, A.; Horst, H. -A.; Marienfeld, K.; Lange, C. 分享 收藏 Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settingsStocker, H; Kloft, C; Plock, N; Breske, A; Kruse, G; Herzmann, C; Schulbin, H; Kreckel, P; Weber, C; Goebel, F; Roeling, J; Staszewski, S; Plettenberg, A; Moecklinghoff, C; Arastéh, K; Kurowski, M 分享 收藏 Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1Fätkenheuer, G; Pozniak, AL; Johnson, MA; Plettenberg, A; Staszewski, S; Hoepelman, AIM; Saag, MS; Goebel, FD; Rockstroh, JK; Dezube, BJ; Jenkins, TM; Medhurst, C; Sullivan, JF; Ridgway, C; Abel, S; James, IT; Youle, M; van der Ryst, E 分享 收藏 分享 收藏 Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma对高效抗逆转录病毒治疗的反应可强烈预测艾滋病相关淋巴瘤患者的结局Hoffmann, C; Wolf, E; Fätkenheuer, G; Buhk, T; Stoehr, A; Plettenberg, A; Stellbrink, HJ; Jaeger, H; Siebert, U; Horst, HA 分享 收藏 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
